←
UroToday.com126,930 posts
UroToday.com avatar

UroToday.com

@urotoday

Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology

◷ Joined February 2009▧ 43,788 Photos and videos
UroToday.com avatar
UroToday.com@urotoday·3h

Navigating novel treatment options in nonmuscle-invasive #BladderCancer for nurses and APPs - Samantha Steinke, APRN, MSN-FNP, BSN, RN & Brenda Martone, MSN, ANP-BC, AOCNP @NorthwesternMed address coordination within the expanding NMIBC treatment landscape. Novel intravesical agents are supported by manufacturer-provided education covering side effects and administration workflows. Since some treatments require infusion capacity beyond urology's usual space, Nurse Steinke's practice has started coordinating with campus infusion teams, establishing communication pathways as adoption increases. #WatchNow > bit.ly/3T5gHie @NUFeinbergMed @LurieCancer

Post attachment
UroToday.com avatar
UroToday.com@urotoday·4h

Restricted Mean Survival Time Analysis of First-Line IO Combinations in Advanced RCC. How much survival do first-line IO combinations add in advanced #RCC? @yuish_uro joins @PBarataMD to discuss a restricted mean survival time analysis of 4 phase 3 trials; ipi-nivo was most cost-effective per month gained. #WatchNow > bit.ly/4jCq43I

1:24
UroToday.com avatar
UroToday.com@urotoday·5h

Comparison of Aquablation with TURP in Benign Prostatic Hyperplasia. Is aquablation the new go-to for #BPH? @dsui_miami_uro joins Alan Wein, MD, PhD(hon), FACS to compare aquablation with TURP and highlights its better preservation of ejaculatory and sexual function. #WatchNow > bit.ly/4jXB37Z

2:04
UroToday.com avatar
UroToday.com@urotoday·7h

Intravesical Gentamicin Instillations for Recurrent Urinary Tract Infections. Recurrent #UTI in neurogenic bladder: Anne Pelletier Cameron, MD, FRCSC, URPS @UMich joins Alan J. Wein, MD, PhD(hon), FACS @dsui_miami_uro to discuss intravesical gentamicin, which cut lab-proven symptomatic UTIs from 3.9 to 1.1 per year. #WatchNow on UroToday > bit.ly/4jWfYuA

2:04
UroToday.com avatar
UroToday.com@urotoday·9h

Proactive adverse event management for talazoparib plus enzalutamide in metastatic APMS. @CaPsurvivorship @DanaFarber joins @neerajaiims @huntsmancancer to discuss anemia management in the TALAPRO-3 regimen. The trial added talazoparib to enzalutamide in HRR-mutated metastatic hormone-sensitive prostate cancer, achieving 52% rPFS risk reduction. Dr. Morgans recommends an anemia panel at baseline to identify correctable causes before attributing low hemoglobin to treatment. #WatchNow > bit.ly/45AOzWS

Post attachment
UroToday.com avatar
UroToday.com@urotoday·Nov 17

Dose-Intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial Can dose intensification improve PSMA radioligand therapy in #mCRPC? The rationale behind OPTIMAL-PSMA, a randomized phase 2 trial of dose-intensified 177Lu-PSMA. #AuthorCommentary with Sobia Khan, Gemma Sheehan-Dare, and @drlouiseemmett > bit.ly/4dVAxDJ

Post attachment
UroToday.com avatar
UroToday.com@urotoday·Nov 17

Practical management of nonmuscle-invasive #BladderCancer treatment in the clinic. Samantha Steinke, APRN, MSN-FNP, BSN, RN & Brenda Martone, MSN, ANP-BC, AOCNP @NorthwesternMed review practical intravesical BCG administration. Therapy uses a Foley catheter with a two-hour dwell time, administered either at home or in the clinic based on patient preference and travel distance. Common self-limited side effects, such as urinary frequency, urgency, and low-grade fever, generally appear by treatment three or four, with onset delayed until later that day and typically resolving within 48 hours. #WatchNow > bit.ly/3UVFdmp @NUFeinbergMed @LurieCancer #NMIBC

Post attachment